• Consensus Rating: Sell
  • Consensus Price Target: $10.33
  • Forecasted Upside: -18.76%
  • Number of Analysts: 3
  • Breakdown:
  • 2 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$12.72
▼ -0.51 (-3.85%)

This chart shows the closing price for VTRS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Viatris Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VTRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VTRS

Analyst Price Target is $10.33
▼ -18.76% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Viatris in the last 3 months. The average price target is $10.33, with a high forecast of $11.00 and a low forecast of $9.00. The average price target represents a -18.76% upside from the last price of $12.72.

This chart shows the closing price for VTRS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 3 polled investment analysts is to sell stock in Viatris. This Sell consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 2 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 2 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 2 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 2 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 2 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 2 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 2 sell ratings
1/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 2 sell ratings
2/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/22/2023Piper SandlerBoost TargetNeutral ➝ Neutral$10.00 ➝ $11.00N/A
10/23/2023Bank of AmericaDowngradeNeutral ➝ Underperform$13.00 ➝ $9.00N/A
6/23/2023BarclaysDowngradeEqual Weight ➝ Underweight$11.00N/A
4/24/2023BarclaysDowngradeOverweight ➝ Equal Weight$11.00N/A
2/28/2023BarclaysBoost TargetOverweight$15.00 ➝ $16.00N/A
2/17/2023BMO Capital MarketsDowngradeOutperform ➝ Market Perform$16.00 ➝ $14.00N/A
2/1/2023BarclaysLower TargetOverweight$16.00 ➝ $15.00N/A
1/27/2023Jefferies Financial GroupUpgradeHold ➝ Buy$13.00 ➝ $15.00N/A
11/15/2022JPMorgan Chase & Co.Boost TargetNeutral$13.00 ➝ $14.00N/A
11/9/2022UBS GroupUpgradeSell ➝ Neutral$9.00 ➝ $12.00N/A
11/8/2022Piper SandlerUpgradeUnderweight ➝ Neutral$10.00N/A
11/7/2022Chardan CapitalDowngradeBuy ➝ NeutralN/A
10/25/2022BarclaysLower TargetOverweight$21.00 ➝ $16.00N/A
10/20/2022Jefferies Financial GroupInitiated CoverageHold$11.00N/A
6/13/2022UBS GroupInitiated CoverageSell$9.00N/A
5/10/2022Piper SandlerDowngradeNeutral ➝ Underweight$10.00N/A
3/16/2022Piper SandlerLower TargetNeutral$17.00 ➝ $10.00N/A
3/10/2022CitigroupLower TargetNeutral$16.00 ➝ $11.00N/A
3/1/2022BMO Capital MarketsLower Target$23.00 ➝ $19.00N/A
3/1/2022Raymond JamesDowngradeOutperform ➝ Market PerformN/A
3/1/2022Bank of AmericaDowngradeBuy ➝ Neutral$21.00 ➝ $13.00N/A
6/15/2021CitigroupInitiated CoverageNeutralN/A
4/7/2021Royal Bank of CanadaInitiated CoverageOutperform$24.00N/A
3/16/2021Morgan StanleyLower TargetEqual Weight$18.00 ➝ $16.00N/A
3/15/2021The Goldman Sachs GroupReiterated RatingBuy ➝ Neutral$20.00 ➝ $15.00N/A
3/12/2021Piper SandlerLower TargetNeutral$17.00 ➝ $16.00N/A
3/10/2021Morgan StanleyLower TargetEqual Weight$18.00 ➝ $16.00N/A
3/8/2021JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$18.00N/A
3/8/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$20.00 ➝ $15.00N/A
3/2/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$21.00 ➝ $18.00N/A
3/1/2021Raymond JamesLower TargetOutperform$23.00 ➝ $19.00N/A
2/26/2021Wolfe ResearchDowngradeOutperform ➝ Market Perform$17.00N/A
2/23/2021Raymond JamesLower TargetOutperform$23.00 ➝ $19.00N/A
2/23/2021BarclaysLower TargetOverweight$26.00 ➝ $20.00N/A
2/8/2021SVB LeerinkReiterated RatingMarket PerformN/A
1/25/2021Raymond JamesLower TargetOutperform$27.00 ➝ $23.00N/A
1/5/2021ArgusInitiated CoverageHoldN/A
12/14/2020Sanford C. BernsteinInitiated CoverageMarket Perform$21.00N/A
11/24/2020Edward JonesInitiated CoverageSellN/A
11/19/2020The Goldman Sachs GroupInitiated CoverageBuy$22.00N/A
11/18/2020Edward JonesInitiated CoverageSellN/A
11/18/2020BarclaysLower TargetOverweight$27.00 ➝ $25.00N/A
11/13/2020Bank of AmericaInitiated CoverageBuyN/A
(Data available from 2/28/2019 forward)

News Sentiment Rating

0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/2/2023
  • 5 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/1/2023
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/1/2023
  • 4 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/31/2023
  • 4 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/30/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/30/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2024
  • 3 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/28/2024

Current Sentiment

  • 3 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Viatris logo
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Read More

Today's Range

Now: $12.72
Low: $12.71
High: $13.55

50 Day Range

MA: $11.82
Low: $10.45
High: $13.53

52 Week Range

Now: $12.72
Low: $8.74
High: $13.62

Volume

7,976,656 shs

Average Volume

10,194,326 shs

Market Capitalization

$15.26 billion

P/E Ratio

8.42

Dividend Yield

3.57%

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Viatris?

The following sell-side analysts have issued reports on Viatris in the last twelve months: Bank of America Co., Barclays PLC, Piper Sandler, and TheStreet.
View the latest analyst ratings for VTRS.

What is the current price target for Viatris?

3 Wall Street analysts have set twelve-month price targets for Viatris in the last year. Their average twelve-month price target is $10.33, suggesting a possible downside of 19.8%. Barclays PLC has the highest price target set, predicting VTRS will reach $11.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $9.00 for Viatris in the next year.
View the latest price targets for VTRS.

What is the current consensus analyst rating for Viatris?

Viatris currently has 2 sell ratings and 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe VTRS will underperform the market and that investors should sell shares of Viatris.
View the latest ratings for VTRS.

What other companies compete with Viatris?

How do I contact Viatris' investor relations team?

Viatris' physical mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company's listed phone number is (724) 514-1800 and its investor relations email address is [email protected]. The official website for Viatris is www.viatris.com. Learn More about contacing Viatris investor relations.